Regenxbio Inc. announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. The company also announced that a pivotal programme for RGX-121 is active and enrolling patients. RGX-121 is an investigational, one-time AAV Therapeutic using the NAV AAV9 vector to deliver the gene that encodes the iduronate-2-sulfatase (I2S) enzyme. "We are pleased to share that our recent discussions with the FDA support our plans to submit a BLA for RGX-121 in 2024 using the accelerated approval pathway, which was created to allow for expedited development of drugs that treat serious conditions and provide a meaningful advantage over available therapies based on a surrogate endpoint," said Kenneth T. Mills, president and chief executive officer of Regenxbio. "We believe RGX-121 for the treatment of Hunter syndrome has demonstrated emerging positive impact on neurodevelopmental function, and we intend to advance this program as quickly as possible with the aim of providing a much-needed new treatment option for the MPS II community." "The accelerated approval pathway gives patients access to potentially life-changing therapeutics sooner, which is why it is a critical tool for the over 7,000 rare diseases, most of which lack FDA-approved treatments," said Joseph Muenzer, MD, PhD, Bryson Distinguished Professor in Paediatrics Genetics, and director, MPS Research and Treatment Programme, University of North Carolina at Chapel Hill. "Boys with MPS II do not have time to wait. I am encouraged by FDA's commitment to advance therapies for rare diseases and their willingness to consider this important pathway for RGX-121." The ongoing phase I/II trial of RGX-121 in children up to five years old has been expanded into a pivotal phase I/II/III trial, named CAMPSIITE. A BLA filing in 2024 is expected to be supported by endpoints in the pivotal programme, including changes from baseline of glycosaminoglycans (GAGs) in the cerebrospinal fluid (CSF) at four months. GAGs in the CSF have the potential to be considered a surrogate biomarker that is reasonably likely to predict clinical benefit in MPS II disease under the accelerated approval pathway, as buildup of GAGs in the CSF of MPS II patients correlates with clinical manifestations, including neurodevelopmental deficits. As presented in February 2022, preliminary results from Regenxbio's phase I/II trial of RGX-121 indicated that RGX-121 continued to be well-tolerated with dose-dependent reductions of GAGs in the CSF, with patients in Cohort 3 approaching normal levels of certain GAGs in the CSF. Measures of neurodevelopmental function from patients in Cohorts 1 and 2 demonstrated continued developmental skill acquisition up to 2 years after RGX-121 administration. "MPS II families are in need of a treatment option that can address the neurodevelopmental decline associated with this disease that available enzyme replacement therapies cannot," said Terri Klein, president and CEO of the National MPS Society. "We are encouraged by today's announcement and the hope that a one-time gene therapy offers this community." CAMPSIITE is a multicenter, open-label trial enrolling boys with MPS II, aged 4 months up to five years of age. CAMPSIITE is now expected to enroll up to 10 MPS II patients to support the BLA filing using the accelerated approval pathway, with the potential to enroll additional patients. These patients will receive a dose of 2.9x1011 GC/g of brain mass of RGX-121, which is the same dose being evaluated in Cohort 3 of the phase I/II trial. The pivotal program is using commercial-scale cGMP material from Regenxbio's proprietary, high-yielding suspension-based manufacturing process, named NAVXPress. In addition to measuring GAGs in the CSF, the trial will continue to collect neurodevelopmental data and caregiver-reported outcomes. CAMPSIITE is a global trial, which is expected to include sites in the United States, Brazil and Canada. Regenxbio has begun dosing patients in the pivotal programme. "MPS II patients face irreversible neurodevelopmental decline that significantly impacts a child's daily life and life expectancy," said Paul Harmatz, MD, professor, UCSF Department of Paediatrics, and principal investigator of the CAMPSIITE study. "Current therapies are inadequate, so we are excited to be a part of this study and eager to see the potential impact on patients." Regenxbio plans to share new RGX-121 data at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium on August 31, 2022. RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene (IDS) which encodes the iduronate-2-sulfatase (I2S) enzyme to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted I2S beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS and consequent reduction of GAGs. RGX-121 has received orphan drug product, rare paediatric disease and Fast Track designations from the US Food and Drug Administration. RGX-121 is being evaluated in two on-going studies, CAMPSIITE, a phase I/II/III multicenter, open-label clinical trial of patients up to five years old with MPS II and a phase I/II multicenter, open-label clinical trial in patients over the age of five years old with MPS II. MPS II, or Hunter syndrome, is a rare, X-linked recessive disease caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase (I2S) leading to an accumulation of glycosaminoglycans (GAGs) in tissues which ultimately results in cell, tissue, and organ dysfunction, including in the central nervous system (CNS). MPS II is estimated to occur in 1 in 100,000 to 170,000 births. In severe forms of the disease, early developmental milestones may be met, but developmental delay is readily apparent by 18 to 24 months. Specific treatment to address the neurological manifestations of MPS II remains a significant unmet medical need. Key biomarkers of I2S enzymatic activity in MPS II patients have been shown to correlate with neurodevelopmental manifestations of the disorder. Regenxbio is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!